timothy sykes logo
FDA Requests More Data, IBRX Shares Fall Thumbnail
ADD US ONG Google News

FDA Requests More Data, IBRX Shares Fall

BRYCE TUOHEY•UPDATED JAN. 26, 2026, 5:04 PM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

ImmunityBio Inc.’s stocks have been trading down by -4.81 percent amid ongoing concerns over pipeline progress and financial health.

Candlestick Chart

Live Update At 17:03:43 EST: On Monday, January 26, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -4.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio Inc. has been on rocky waters financially, reflected in recent turbulent earnings. The biotech entity posted negative earnings per share, and it continues grappling with substantial losses. Revenue sits stagnant at $14.75 million giving a look into its distressing pricing relative to cash flow. The company holds hefty debt, positioning its future profitability at risk. Despite a good gross margin calculation, financial strength remains thin.

Analyzing its past performance, IBRX seems locked in a precarious dance between innovation and fiscal imperilment. Cash flows appear turbulent with substantial capital expenditures and long-term debt repayments. Hence, the persistent negative momentum surrounding the stock. Given the latest reported numbers, current ratios signal liquidity stress, but amid these financial struggles lies the potential for breakthrough.

Market Reactions to FDA’s Information Request

The FDA’s request has undoubtedly cast a shadow over ImmunityBio’s progress. Investors eager for smooth regulatory processes faced jarring reality as the stock lost its pace. Often, these FDA queries bring along a veil of uncertainty, a specter few companies wish to encounter. Questions arise over ImmunityBio’s preparedness, the efficacy of the treatment, or merely procedural delays.

Although Anktiva plus Bacillus Calmette-Guerin promises to address unmet medical needs, the ask for further data means the road to market is longer than expected. For many in the biotech world, the balance between scientific ambition, regulatory clearances, and shareholder satisfaction is a complex one.

Consequently, the share prices performing a downward spin is a likely event. Biotech enthusiasts seasoned in the market exact similar patterns upon extended regulatory assessments, sometimes halting momentum that valuations otherwise built over time in anticipation of positive approvals.

More Breaking News

Conclusion

In a market buzzing with instant reactions to the smallest of developments, ImmunityBio’s current narrative is one of waiting, watching, and wondering. The FDA’s request for more information about its flagship treatment thrusts the biotech firm into a spotlight of scrutiny. As shares take a hit, the promise of its innovative treatment remains at the forefront of conversations surrounding ImmunityBio’s volatile prospects. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This is especially important for traders navigating the uncertain waters of biotechnological aspirations.

As stories develop, the intertwined nature of health innovations, regulatory rigor, and market expectations will continue to shape the unfolding canvas of ImmunityBio’s journey in the volatile sea of biotechnological aspirations.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”